| Grade 3a Follicular Lymphoma studied in …STUDIED_INderived38 of 38show fewer |
|---|
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07731789Phase 2 · not yet recruiting Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01849263Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06442475Phase 2 · recruiting Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150329Phase 1 · active not recruiting Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404088Phase 2 · active not recruiting Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06471738Phase 2 · recruiting Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03269669Phase 2 · active not recruiting Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520791Phase 1 · active not recruiting Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205409Phase 2 · completed Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948786Phase 2 · recruiting Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169658Phase 2 · completed Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07545603Phase 2 · recruiting Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma · condition mapped ALIAS · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859008Phase 1 · recruiting Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04450173Phase 2 · active not recruiting Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446457Phase 2 · active not recruiting Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883437Phase 2 · recruiting Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06575686Phase 2 · suspended Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02568553Phase 1 · completed Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01286272Phase 2 · completed Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01995669Phase 1/Phase 2 · completed Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02871219Phase 2 · completed Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05326243Phase 1/Phase 2 · recruiting Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377307recruiting Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy · condition mapped ALIAS · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06961500Phase 2 · not yet recruiting Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A · condition mapped ALIAS · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03410901Phase 1 · completed TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927964Phase 1/Phase 2 · completed TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02532257Phase 2 · completed Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04659044Phase 2 · terminated Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04995536Phase 1 · withdrawn CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03010358Phase 1/Phase 2 · completed Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04635683Phase 1 · withdrawn Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02710643Phase 2 · completed "MIRO" Molecularly Oriented Immuno-radio-therapy · condition mapped ALIAS · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02950220Phase 1 · completed Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 38 trials mapped (21 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |